Related Experiment Videos
Antiarrhythmic therapy for ventricular arrhythmias
1Cardiology Center, University Hospital, Geneva, Switzerland.
Insights
Treating ventricular arrhythmias requires careful consideration of patient symptoms and sudden death risk. Risk stratification is crucial to avoid unnecessary antiarrhythmic drug therapy and potential adverse effects.
Area of Science:
- Cardiology
- Clinical Electrophysiology
- Pharmacology
Background:
- Treatment of ventricular arrhythmias has been a major focus for two decades.
- Recent trials with Class I antiarrhythmic drugs post-myocardial infarction challenge the established risk-benefit ratio, particularly in asymptomatic patients.
Purpose of the Study:
- To re-evaluate the indications for treating ventricular arrhythmias.
- To emphasize the importance of risk stratification in selecting patients for antiarrhythmic therapy.
Main Methods:
- Review of recent clinical trials and theoretical considerations regarding antiarrhythmic drug efficacy and safety.
- Assessment of factors influencing the prognostic significance of ventricular arrhythmias.
Main Results:
- The decision to treat ventricular arrhythmias should be based on symptom presence or increased risk of sudden cardiac death.
- Prognostic significance is influenced by underlying cardiac disease, left ventricular function, symptoms, and arrhythmia characteristics.
Conclusions:
- A comprehensive risk stratification strategy is essential for appropriate patient selection for antiarrhythmic therapy, including non-pharmacological treatments.
- This approach helps avoid unnecessary treatment and mitigate risks associated with antiarrhythmic agents, such as proarrhythmic or negative inotropic effects.
Abstract:
Treatment of ventricular arrhythmias has received great attention during the past 20 years. However, results of recent trials with class I antiarrhythmic drugs in patients after myocardial infarction have raised many questions about the risk-benefit ratio of antiarrhythmic therapy, at least in asymptomatic subjects. Theoretically, the only two reasons to treat ventricular arrhythmias are (a) the presence of symptoms related to the arrhythmia, and (b) the presence of an increased risk of sudden death. The prognostic significance of a ventricular arrhythmia depends on the type of underlying cardiac disease, on the extent of left ventricular dysfunction, on arrhythmia-related symptoms, and on specific characteristics of the ventricular arrhythmia itself. All these factors should be assessed to allow an adequate selection of patients who really need antiarrhythmic therapy (including nonpharmacological modes of treatment), and to allow the identification of patients for whom antiarrhythmic therapy is clearly unnecessary. Such a risk stratification strategy is essential, because many if not all antiarrhythmic agents have potentially serious adverse effects such as proarrhythmic or negative inotropic effects.